ArticleCureus2025
Adrenal Insufficiency Induced by Checkpoint Inhibitor Therapy in a Patient With Metastatic Acral Melanoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced melanoma; however, their clinical benefit is tempered by a widening spectrum of immune-related adverse events (irAEs), including endocrine dysfunction. Among these, hypophysitis and adrenal insufficiency remain under-recognised, yet potentially life-threatening complications. We describe a case of secondary adrenal insufficiency in a 78-year-old female with unresectable Stage IIIC acral melanoma treated with nivolumab and relatlimab. She presented with profound hyponatraemia, hypotension, and fatigue. Subsequent evaluation confirmed central adrenal insufficiency. Glucocorticoid replacement led to rapid clinical improvement. This case underscores the imperative for heightened clinical vigilance in patients receiving ICI therapy. Recognition and prompt intervention are crucial to reducing morbidity and optimising oncologic and endocrine outcomes, which could range from thyroid dysfunction and adrenal insufficiency to hypophysitis, as the case underscores the clinical complexity of diagnosing ICI-related endocrinopathies and highlights the need for high clinical vigilance and structured endocrine surveillance in patients undergoing immune checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.